At a glance
ClinicalIndex Comparison RecordN/ARecruiting· 120 target
Drug / intervention
CardioMEMS HF Systemdevice
Likely dose
Not stated in record
Key inclusion· 8
- ✓Diagnosis of pulmonary hypertension Group I, II, III, or IV
- ✓Age 18 years or older
- ✓eGFR greater than 25
- ✓BMI less than 35 or equivalent
Key exclusion· 8
- ✕Group IV pulmonary hypertension
- ✕Active infection
- ✕Pulmonary embolus or deep vein thrombosis
- ✕Major cardiovascular event within past 2 months
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Feasibility of Novel Clinical Trial Infrastructure, Design and Technology for Early Phase Studies in Patients With Pulmonary Hypertension.
Sheffield Teaching Hospitals NHS Foundation Trust·observational·Posted Sep 6, 2019·Updated Jun 4, 2025
In Brief
An observational study evaluating CardioMEMS HF System for Pulmonary Hypertension. Currently recruiting, targeting 120 participants across 1 site.
Detailed Summary
Prospective, open-label, observational study to evaluate the safety and feasibility of using pulmonary artery pressure (PAP) monitors and wearable activity monitors in patients with pulmonary hypertension (PH).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Hypertension
CountriesUnited Kingdom
Collaborators--
Timeline
N/ARecruiting
202020212022202320242025202620272028
First PostedSep 2019
Enrollment StartJan 2020
TodayJul 2026
Primary CompletionJan 2028
Study CompletionSep 2028
First PostedSep 6, 2019
Enrollment StartJan 21, 2020
Primary CompletionJan 6, 2028
Study CompletionSep 6, 2028
TodayJul 2, 2026
Enrollment to primary: 8.0 yearsPosted 6.8 years agoPrimary completion in 1.5 years
Interventions
CardioMEMS HF Systemdevice
The CardioMEMS HF System is the first and only FDA-approved wireless heart failure monitor. The system is a safe, reliable way to help your patients manage their heart failure.